![CalciMedica Inc](/common/images/company/N_CALC.png)
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune... CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2 | -7.38007380074 | 2.71 | 2.75 | 2.3675 | 16849 | 2.6604037 | CS |
4 | -0.66 | -20.8201892744 | 3.17 | 3.2208 | 2.32 | 33282 | 2.66683223 | CS |
12 | -0.94 | -27.2463768116 | 3.45 | 3.67 | 2.05 | 44658 | 2.90191333 | CS |
26 | -1.88 | -42.8246013667 | 4.39 | 5.97 | 2.05 | 49144 | 3.63745287 | CS |
52 | -2.72 | -52.0076481836 | 5.23 | 6.265 | 2.05 | 39962 | 3.90103053 | CS |
156 | -13.87 | -84.6764346764 | 16.38 | 16.38 | 1.17 | 17618 | 3.91444328 | CS |
260 | -13.87 | -84.6764346764 | 16.38 | 16.38 | 1.17 | 12088 | 3.91444328 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관